Figure 1.
Patient disposition. ∗Includes patients intolerant of ibrutinib and acalabrutinib. CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma.

Patient disposition. ∗Includes patients intolerant of ibrutinib and acalabrutinib. CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal